Science Current Events | Science News |

Anti-HIV drug simulation offers 'realistic' tool to predict drug resistance and viral mutation

September 04, 2012

Computer model should help develop better anti-HIV drug combination therapies

Pooling data from thousands of tests of the antiviral activity of more than 20 commonly used anti-HIV drugs, AIDS experts at Johns Hopkins and Harvard universities have developed what they say is the first accurate computer simulation to explain drug effects. Already, the model clarifies how and why some treatment regimens fail in some patients who lack evidence of drug resistance. Researchers say their model is based on specific drugs, precise doses prescribed, and on "real-world variation" in how well patients follow prescribing instructions.

Johns Hopkins co-senior study investigator and infectious disease specialist Robert Siliciano, M.D., Ph.D., says the mathematical model can also be used to predict how well a patient is likely to do on a specific regimen, based on their prescription adherence. In addition, the model factors in each drug's ability to suppress viral replication and the likelihood that such suppression will spur development of drug-resistant, mutant HIV strains.

"With the help of our simulation, we can now tell with a fair degree of certainty what level of viral suppression is being achieved - how hard it is for the virus to grow and replicate - for a particular drug combination, at a specific dosage and drug concentration in the blood, even when a dose is missed," says Siliciano, a professor at the Johns Hopkins University School of Medicine and a Howard Hughes Medical Institute investigator. This information, he predicts, will remove "a lot of the current trial and error, or guesswork, involved in testing new drug combination therapies."

Siliciano says the study findings, to be reported in the journal Nature Medicine online Sept. 2, should help scientists streamline development and clinical trials of future combination therapies, by ruling out combinations unlikely to work.

One application of the model could be further development of drug combinations that can be contained in a single pill taken once a day. That could lower the chance of resistance, even if adherence is not perfect. Such future drug regimens, he says, will ideally strike a balance between optimizing viral suppression and minimizing risk of drug resistance.

Researchers next plan to expand their modeling beyond blood levels of virus to other parts of the body, such as the brain, where antiretroviral drug concentrations can be different from those measured in the blood. They also plan to expand their analysis to include multiple-drug-resistant strains of HIV.

Besides Siliciano, Johns Hopkins joint medical-doctoral student Alireza Rabi was a co-investigator in this study. Other study investigators included doctoral candidates Daniel Rosenbloom, M.S.; Alison Hill, M.S.; and co-senior study investigator Martin Nowak, Ph.D. - all at Harvard University.

Funding support for this study, which took two years to complete, was provided by the National Institutes of Health, with corresponding grant numbers R01-MH54907, R01-AI081600, R01-GM078986; the Bill and Melinda Gates Foundation; the Cancer Research Institute; the National Science Foundation; the Howard Hughes Medical Institute; Natural Sciences and Engineering Research Council of Canada; the John Templeton Foundation; and J. Epstein.

Currently, an estimated 8 million of the more than 34 million people in the world living with HIV are taking antiretroviral therapy to keep their disease in check. An estimated 1,178,000 in the United States are infected, including 23,000 in the state of Maryland.


For additional information, go to:

Johns Hopkins Medicine

Related Combination Therapies Current Events and Combination Therapies News Articles

Ancient anti-inflammatory drug salicylic acid has cancer-fighting properties
Scientists from the Gladstone Institutes have identified a new pathway by which salicylic acid--a key compound in the nonsteroidal anti-inflammatory drugs aspirin and diflunisal--stops inflammation and cancer.

Researchers reveal how a new class of drugs kills cancer cells
A team of Walter and Eliza Hall Institute researchers has worked out how a new class of anti-cancer drugs kills cancer cells, a finding that helps explain how cancer cells may become resistant to treatment.

A long-noncoding RNA regulates repair of DNA breaks in triple-negative breast cancer cells
The discovery of long non-coding RNA (lncRNA) has dramatically changed the understanding of the biology of diseases such as cancer.

Researchers find method that could resurrect an abandoned pancreatic cancer targeted drug
Pancreatic cancer is on track to become the second leading cause of cancer-related deaths by 2020.

Curbing malaria resistance with multiple therapies
In order to preserve first-line drugs for treating malaria, multiple combination therapies should be deployed within a population to prevent resistance from developing, according to Maciej Boni from the Centre for Tropical Medicine and Global Health, University of Oxford, UK, and colleagues in a Policy Forum article published in this week's PLOS Medicine.

Medication protects fertility and defense system during chemotherapy
While targeted cancer treatments have reduced side effects and improved efficacy, chemotherapy remains the backbone of combination therapies for many forms of cancer.

UA-led research: Prevention of macular degeneration possible
A University of Arizona-led study on age-related macular degeneration - the eye disease that gradually destroys the ability to read, drive, write and see close-up in 30 percent of older Americans - likely will lead to a way to delay or prevent the disease, researchers say.

Treatment restores some function in animal models of spinal muscular atrophy
In work involving several new generations of mouse model development, Jackson Laboratory (JAX) researchers have tested a therapeutic intervention for spinal muscular atrophy (SMA) that restores some function lost due to a mutation in one gene (SMN1) and amplifies the levels of protective genes (SMN2).

Professor Janet Hemingway, outlines 15 years of malaria interventions in Africa
In an editorial in the weekly science journal Nature, LSTM's Director, Professor Janet Hemingway, looks at how the last 15 years of control measures have led to massive reductions in disease prevalence in Africa since 2000.

Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.
More Combination Therapies Current Events and Combination Therapies News Articles

Textbook of Facial Rejuvenation: The Art of Minimally Invasive Combination Therapy

Textbook of Facial Rejuvenation: The Art of Minimally Invasive Combination Therapy
by Nicholas J. Lowe (Editor), Alastair Carruthers (Editor), Jean Carruthers (Editor), Zoe Diana Draelos (Editor), Richard Glogau (Editor), Christopher Griffiths (Editor), Arnold W. Klein (Editor), Gary Lask (Editor)

In recent years the demand for rejuvenating treatments for the face has grown dramatically for both men and women. Alongside that demand, a wide variety of treatments have evolved, and a combination of different treatments can often result in much greater improvement than single-treatment approaches. With contributions from an impressive cast of international experts, Textbook of Facial Rejuvenation details current treatments, recommends approaches, and suggests how they may be tailored towards individual needs and combined for optimum results.

Combination Therapy In Dyslipidemia

Combination Therapy In Dyslipidemia
by Maciej Banach (Editor)

Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia.Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on...

Hematology - Oncology Therapy

Hematology - Oncology Therapy
by Michael Boyiadzis (Author), James Frame (Author), David R. Kohler (Author), Tito Fojo (Author)

The Essential Therapy Guide to Cancer, Hematologic Disorders, and Supportive Care--Updated with the Latest Treatment Regimens More than 500 treatment regimens Hematology-Oncology Therapy, Second Edition is an up-to-date, comprehensive therapy guide that delivers more than 500 treatment regimens in a succinct, uniform manner. The unique tabular design allows you to instantly locate and implement the proper treatment regimen. Supported by the latest practice guidelines, peer-reviewed literature, and the opinion of experts, Hematology-Oncology Therapy integrates extensive information that is critical to both office- and hospital-based practice of hematology and oncology. Hematology-Oncology Therapy is divided into three sections: Oncology:
Provides detailed information about the...

Recent Developments in Anti-Fungal Agents: Perspective for Combination Therapies in Treatment of Invasive Fungal Infections

Recent Developments in Anti-Fungal Agents: Perspective for Combination Therapies in Treatment of Invasive Fungal Infections
by Mohd. Shahid (Author), Trivendra Tripathi (Author)

Invasive fungal infections (IFIs) demand a tremendous levy in terms of human life and healthcare costs, despite the fact that fungal diseases are still under-diagnosed and under reported. Several factors such as patient characteristics, antifungal prophylaxis and others appear to have contributed to a change in the spectrum of invasive fungal pathogens (i.e. Candida species, Non-Candida species, Aspergillus species and Non-Aspergillus species). Therefore, it is important to recognize and minimize the major risk factors associated with infection, and expanding the antifungal drug research for new antifungal agents to treat life-threatening invasive infections. This book would highlight past and current research on fungal pathogens and antifungal therapies, and also novel targets for...

Antiepileptic Drugs: Combination Therapy and Interactions

Antiepileptic Drugs: Combination Therapy and Interactions
by Jerzy Majkowski (Editor), Blaise F. D. Bourgeois (Editor), Philip N. Patsalos (Editor), Richard H. Mattson (Editor)

This book reviews the use of antiepileptic drugs focusing on the interactions between these drugs and between antiepileptics and other drugs. These interactions can be beneficial or can cause harm. The aim of this book is to increase awareness of the possible impact of combination pharmacotherapies. Pharmacokinetic and pharmacodynamic interactions are discussed supported by clinical and experimental data. The book consists of five sections covering the general concepts and advantages of combination therapies, the principles of drug interactions, the mechanisms of interactions, drug interactions in specific populations or in patients with co-morbid health conditions, and concludes with a look at the future directions for this field of research. The book will be of interest to all who...

RRT, ACCS, SDS-Quick Exam Review Combination Book

RRT, ACCS, SDS-Quick Exam Review Combination Book

This book is a combination of three other books that are meant to be quick exam reviews for the Registered Respiratory Therapy (RRT) written exam, The Adult Critical Care Specialty exam (ACCS), and the Sleep Disorders Specialty exam (SDS). These books are all available individually and what this book does is just combine all three exam reviews into one book. These exam reviews are meant to supplement other books as well as practice tests to help you pass the exams. I hope you find this information helpful in passing the board exams and can advance your career by obtaining these credentials and accomplishments.

Advances in Combination Therapy for Asthma and COPD

Advances in Combination Therapy for Asthma and COPD
by Jan Lotvall (Editor)

Aimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy for Asthma and COPD is the first book to address the complexity of multi-agent therapy and deal with management issues in an integrated fashion.  A review of currently available agents and their applications, as well as new therapies soon to become available are outlined. Advantages of combined therapies and additional considerations that arise from multi-agent programs are highlighted.

Acupuncture Point Combinations: The Key to Clinical Success, 1e

Acupuncture Point Combinations: The Key to Clinical Success, 1e
by Jeremy Ross (Author)

This book covers the principles and practice of combining acupuncture points - expanding a practitioner's repertoire and increasing their skills - enabling them to use a balanced and appropriate choice of points in the treatment of patients. Information onthe combination of the main points of the fourteen channels is covered in the book prior to outlining specific point combinations for selected disease syndromes. Discussion of combining points according to dermatome theory and according to the energy centres of the body is also discussed, as is combining points for the mind end emotions, and for lifestyle and behaviour. No existing book covers this aspect of clinical practice in such thorough and wide-ranging detail.

Molecular Therapies of Cancer

Molecular Therapies of Cancer
by Georg F. Weber (Author)

Molecular Therapies of Cancer comprehensively covers the molecular mechanisms of anti-cancer drug actions in a comparably systematic fashion. While there is currently available a great deal of literature on anti-cancer drugs, books on the subject are often concoctions of invited review articles superficially connected to one another. There is a lack of comprehensive and systematic text on the topic of molecular therapies in cancer. A further deficit in the relevant literature is a progressive sub-specialization that typically limits textbooks on cancer drugs to cover either pharmacology or medicinal chemistry or signal transduction, rather than explaining molecular drug actions across all those areas; Molecular Therapies of Cancer fills this void. The book is divided into five sections:...

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)
by Gary K. Schwartz (Editor)

Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.

© 2016